Seo S, Choi J, Kim M, Yang E, Choi S, Seo D
Clin Exp Vaccine Res. 2025; 14(1):10-22.
PMID: 39927228
PMC: 11799578.
DOI: 10.7774/cevr.2025.14.e10.
Yan X, Li J, Ma Q, Wang H, Li L, Zhao H
Virol Sin. 2024; 39(6):882-891.
PMID: 39151705
PMC: 11738778.
DOI: 10.1016/j.virs.2024.08.004.
Wen X, Guo J, Sun D, Wang M, Cao D, Cheng A
Vaccines (Basel). 2019; 7(3).
PMID: 31514454
PMC: 6789628.
DOI: 10.3390/vaccines7030111.
Wang Y, Ma L, Stipkovits L, Szathmary S, Li X, Liu Y
Front Microbiol. 2019; 9:2943.
PMID: 30619109
PMC: 6297142.
DOI: 10.3389/fmicb.2018.02943.
McKnight K, Lemon S
Cold Spring Harb Perspect Med. 2018; 8(12).
PMID: 29610147
PMC: 6280712.
DOI: 10.1101/cshperspect.a033480.
The C-terminal region of the non-structural protein 2B from Hepatitis A Virus demonstrates lipid-specific viroporin-like activity.
Shukla A, Dey D, Banerjee K, Nain A, Banerjee M
Sci Rep. 2015; 5:15884.
PMID: 26515753
PMC: 4626808.
DOI: 10.1038/srep15884.
Molecular biology and inhibitors of hepatitis A virus.
Debing Y, Neyts J, Thibaut H
Med Res Rev. 2013; 34(5):895-917.
PMID: 23722879
PMC: 7168461.
DOI: 10.1002/med.21292.
Does mutation of hepatitis A virus exist in North India?.
Hussain Z, Husain S, Pasha S, Anand R, Chand A, Polipalli S
Dig Dis Sci. 2007; 53(2):506-10.
PMID: 17597409
DOI: 10.1007/s10620-007-9870-9.
Diagnosis of hepatitis a virus infection: a molecular approach.
Nainan O, Xia G, Vaughan G, Margolis H
Clin Microbiol Rev. 2006; 19(1):63-79.
PMID: 16418523
PMC: 1360271.
DOI: 10.1128/CMR.19.1.63-79.2006.
Stable growth of wild-type hepatitis A virus in cell culture.
Konduru K, Kaplan G
J Virol. 2006; 80(3):1352-60.
PMID: 16415012
PMC: 1346922.
DOI: 10.1128/JVI.80.3.1352-1360.2006.
Growth of hepatitis A virus in a mouse liver cell line.
Feigelstock D, Thompson P, Kaplan G
J Virol. 2005; 79(5):2950-5.
PMID: 15709014
PMC: 548470.
DOI: 10.1128/JVI.79.5.2950-2955.2005.
Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin-and mucin-like regions.
Silberstein E, Xing L, van de Beek W, Lu J, Cheng H, Kaplan G
J Virol. 2003; 77(16):8765-74.
PMID: 12901378
PMC: 169634.
DOI: 10.1128/jvi.77.16.8765-8774.2003.
Full-length genome of wild-type hepatitis A virus (DL3) isolated in China.
Liu G, Hu N, Hu Y
World J Gastroenterol. 2003; 9(3):499-504.
PMID: 12632505
PMC: 4621569.
DOI: 10.3748/wjg.v9.i3.499.
Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees.
Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle R
Proc Natl Acad Sci U S A. 2002; 99(22):14416-21.
PMID: 12391335
PMC: 137898.
DOI: 10.1073/pnas.212532699.
Mutational characteristics in consecutive passage of rapidly replicating variants of hepatitis A virus strain H2 during cell culture adaptation.
Hu N, Hu Y, Shi H, Liu G, Qu S
World J Gastroenterol. 2002; 8(5):872-8.
PMID: 12378633
PMC: 4656578.
DOI: 10.3748/wjg.v8.i5.872.
Replication of subgenomic hepatitis A virus RNAs expressing firefly luciferase is enhanced by mutations associated with adaptation of virus to growth in cultured cells.
Yi M, Lemon S
J Virol. 2002; 76(3):1171-80.
PMID: 11773393
PMC: 135777.
DOI: 10.1128/jvi.76.3.1171-1180.2002.
Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.
Krieger N, Lohmann V, Bartenschlager R
J Virol. 2001; 75(10):4614-24.
PMID: 11312331
PMC: 114214.
DOI: 10.1128/JVI.75.10.4614-4624.2001.
Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1.
Silberstein E, Dveksler G, Kaplan G
J Virol. 2001; 75(2):717-25.
PMID: 11134285
PMC: 113968.
DOI: 10.1128/JVI.75.2.717-725.2001.
Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function.
Yi M, Schultz D, Lemon S
J Virol. 2000; 74(14):6459-68.
PMID: 10864658
PMC: 112154.
DOI: 10.1128/jvi.74.14.6459-6468.2000.
Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.
Kanno T, Mackay D, Inoue T, Wilsden G, Yamakawa M, Yamazoe R
J Virol. 1999; 73(4):2710-6.
PMID: 10074117
PMC: 104027.
DOI: 10.1128/JVI.73.4.2710-2716.1999.